Research progress in targeted therapy and immunotherapy for gastric cancer
10.1097/CM9.0000000000002185
- VernacularTitle:Research progress in targeted therapy and immunotherapy for gastric cancer
- Author:
Xuewei LI
1
;
Jun XU
;
Jun XIE
;
Wenhui YANG
Author Information
1. Department of Biochemistry and Molecular Biology, Shanxi Key Laboratory of Birth Defect and Cell Regeneration, Shanxi Medical University, Taiyuan, Shanxi 030001, China
- Keywords:
Angiogenesis;
Cytotoxic T lymphocyte-associated antigen-4;
Epidermal growth factor receptor;
Gastric cancer;
Immunotherapy;
Programed cell death ligand 1;
P
- From:
Chinese Medical Journal
2022;135(11):1299-1313
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer (GC) is one of the most common malignant tumors worldwide. Its incidence ranks the 5th among all malignant tumors globally, and it is the 3rd leading cause of death among patients with cancer. Surgical treatment is the first choice in clinical practice. However, targeted therapy, immunotherapy, and other treatment methods have also become research hotspots at home and abroad with the development of individualized precision therapy in recent years, besides traditional radiotherapy and chemotherapy. At present, targeted therapy and immunotherapy are methods used for treating GC, and they have important clinical application value and prospects. This study aimed to review the research progress of targeted therapy and immunotherapy for GC, focusing on its mechanism of action and related important clinical trials, hoping to provide references for the clinical treatment of GC.
